Tirzepatide

Tirzepatide is a first-in-class dual incretin agonist, developed by Eli Lilly, that targets both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Marketed as Mounjaro for type 2 diabetes and Zepbound for weight loss, Tirzepatide has shown unprecedented effectiveness in reducing body fat and improving glycemic control.

By mimicking these two gut hormones, Tirzepatide improves insulin sensitivity, reduces appetite, slows gastric emptying, and enhances satiety — making it a powerful tool for treating obesity, prediabetes, type 2 diabetes, and metabolic syndrome.